Introduction
The Nucleic Acid Delivery Consortium is an innovative academic-industry partnership aimed at addressing the significant challenges associated with delivering nucleic acid-based therapies to targeted organs, tissues, and cells.
The Promise of Nucleic Acid Therapies
Nucleic acid therapies represent a transformative class of medicines that utilise engineered DNA or RNA molecules to treat diseases at their genetic origin. This approach offers the potential for curing a wide array of disorders, including genetic conditions, various cancers, and infectious diseases. Various technologies have emerged within this field, including:
- mRNA
- Short interfering RNAs (siRNA)
- Antisense oligonucleotides (ASOs)
- CRISPR-based gene editing tools
These technologies aim to modulate, replace, or edit genetic code, with initial approved therapies demonstrating remarkable success. However, despite this progress, a common challenge persists across all nucleic acid therapies in development: the ability to effectively reach the target organs, tissues, and cells that are most impacted by diseases.
Formation of the Consortium
To address this delivery bottleneck, the Nucleic Acid Delivery Consortium, led by the Wyss Institute, is bringing together experts from the greater Boston technology ecosystem and beyond. This consortium comprises:
- Researchers from the Wyss Institute who are pioneering new nucleic acid therapies and advanced drug delivery technologies.
- Experts from Wyss spin-out companies focused on advancing nucleic acid therapies, as well as platforms for nucleic acid delivery, synthesis, and analysis.
- Industry specialists from the biotech and pharmaceutical sectors.
This collaborative effort is designed to foster a brain trust that tackles specific delivery challenges and catalyses the development of innovative solutions.
Conclusion
The establishment of the Nucleic Acid Delivery Consortium represents a significant step forward in the quest to enhance the efficacy of nucleic acid therapies. By leveraging the expertise of diverse stakeholders, the consortium aims to unlock new pathways for the delivery of these promising treatments, ultimately paving the way for improved patient outcomes.